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INTRODUCTION 
 President Obama’s Precision Medicine Initiative® (PMI) was announced in January, 
2015 (1). Its goal is to enable a new era of medicine in which researchers, providers, and patients 
work together to develop care that takes into account individual differences in people’s genes, 
environments, and lifestyles. The National Institutes of Health (NIH) has two major PMI 
mandates: to build a large national research cohort and to support precision medicine clinical 
trials to improve cancer treatment and study other aspects of oncology. Public health leaders, 
including National Cancer Institute (NCI) Acting Director Doug Lowy, have commented that 
precision medicine approaches have a place in cancer prevention and screening (2-4). 
Cancer screening in the general population refers to the testing of asymptomatic, average- 
risk individuals. It is an important approach to cancer prevention and control but has limitations. 
At the heart of precision cancer screening is the notion that an individual’s risk of disease, based 
on genetic factors, environmental and lifestyle exposures, and previous screening history, is 
positively correlated with the expected benefit that an individual will receive. If true, more 
precise risk assessment, coupled with modification of screening regimens based on risk, would 
lead to programs that result in more benefit and less harm than do today’s programs.  
 The practice of precision cancer screening is not new. For example, screening guidelines 
and recommendations from leading bodies such as the United States Preventive Services Task 
Force (USPSTF), the American Cancer Society (ACS), and the National Comprehensive Cancer 
Network (NCCN) typically are conditional on age and sex, and for lung cancer, on smoking 
history. Two emerging research areas in precision cancer screening include the use of past 
screening history to recommend future screening regimens and the use of arrays of genetic 
information to allow varied screening regimens to be targeted to individuals based on personal 
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cancer risk. Implementation of certain proposed strategies should wait, however, until 
compelling evidence exists to indicate that such practices likely would increase the net benefit of 
screening programs and be acceptable to patients and clinicians. Metrics of benefit would need to 
reflect extension of life in those who are targeted for screening as well as consequences of 
missed cancers in those who would be excluded based on revised recommendations.    
On September 29, 2015, NCI sponsored a symposium entitled “Precision Cancer 
Screening in the General Population: Evidence, Epidemiology, and Next Steps” (5). The goal 
was two-fold: to share the available evidence, practices, and challenges surrounding precision 
screening for breast, cervical, colorectal, lung, and prostate cancers, and allow for in-depth 
discussion among experts in relevant fields regarding how epidemiology and other population 
sciences can be used to move the field forward. By “general population,” we refer to persons 
without previous diagnosis of cancer or pre-cancer and not known or suspected to be at markedly 
increased or decreased risk due to symptoms, highly penetrant genetic mutations, family history, 
or medical conditions known to increase cancer risk. In this paper, we report on symposium 
presentations and breakout group discussions, themes that emerged from the symposium, and 
thoughts regarding next steps.  
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CHALLENGES AND OPPORTUNITIES FOR PRECISION MEDICINE SCREENING 
FOR COMMON CANCERS  
Morning sessions included overviews of NIH’s PMI cohort, challenges and opportunities 
that would accompany precision cancer screening, and evidence and issues specific to each of 
the five cancers.  
 
NIH's PMI Cohort 
 The multipurpose PMI cohort will provide data that can be used to explore precision 
screening strategies (1). One million volunteers will be recruited, provide a biospecimen, 
complete questionnaires, agree to share health information with researchers, and be recontacted 
for future research. The goals of the cohort that are of most relevance to precision cancer 
screening are quantification of risk associated with genetic and environmental factors (alone and 
in combination) and identification of biomarkers that can indicate degree of cancer risk.  
 
Precision Cancer Screening in the General Population: Challenges and Opportunities 
 Risk assessment is central to precision screening. Once the distribution of risk in the 
general population is known, risk strata can be chosen, and each assigned a unique screening 
regimen. For example, different strata could have regimens that differ with respect to start and 
end ages, screening intervals, and screening modalities (6). Risk assessment can occur either 
before or after the first screening episode. A pre-screening approach enables selection of patients 
for risk-tailored regimens and could perhaps guide diagnostic evaluation decisions following 
abnormal screening exams.  
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Genetic and non-genetic risk factors could be used for risk assessment. To date, genome-
wide association studies have identified over 90 breast cancer susceptibility variants (7), and the 
receiver-operating characteristic curve derived from a polygenic risk profile based on these 
variants has an area under the curve (AUC) of 0.65 (derived from data presented in (7)). 
Addition of non-genetic risk factors, like age at menarche, parity, age at first live birth, oral 
contraceptive use, body mass index, alcohol, smoking, personal history of benign breast disease, 
and family history of breast cancer in first-degree relatives, increases the AUC to 0.68 (8). In the 
hypothetical instance of restricting screening to women above the 30th percentile of risk, addition 
of non-genetic factors would increase screen detection from 50% to 58% of all cases (derived 
from data presented in (7) and (8)).  
Use of a precision screening strategy within the general population has the potential to 
improve the efficiency of screening programs and reduce adverse consequences. Examination of 
a possible risk-stratified screening strategy for breast cancer, with eligibility based on absolute 
risk calculated using age and polygenic risk score, suggests that the number needed to screen to 
prevent one cancer death could be reduced while detecting most cancers identified by a 
conventional age-based strategy (9). Modeling studies suggest that restriction of prostate cancer 
screening to men at higher than average risk based on polygenic information could reduce the 
proportion of screen-detected prostate cancers that are likely to represent overdiagnosis (10, 11). 
Evidence is lacking as to the impact on net benefit or harm of these strategies, and 
implementation clearly would pose numerous organizational challenges, most notably 
ascertainment of genomic information, and raise ethical and legal questions. Of great importance 
is that willingness of patients to accept such strategies is unknown.  
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Breast Cancer Screening 
 Most breast cancer screening recommendations for women in the general population 
specify starting and ending ages and screening intervals without regard to other individual 
characteristics, including breast cancer risk factors. Some organizations, including the ACS, 
recommend that cessation be based on life expectancy (12). Breast density is under consideration 
as a stratification factor, as it is associated with both increased breast cancer risk and decreased 
mammographic sensitivity; women with dense breasts could receive screening that begins 
earlier, occurs more frequently, or uses more sensitive modalities, either alone or as adjuncts to 
mammography. Certain published analyses that aimed to identify subgroups for whom screening 
before age 50 was beneficial suggest that women with extremely dense breasts may benefit from 
beginning screening in their forties (13) and by choosing an annual rather than biennial interval 
(14). No direct evidence supports use of supplemental ultrasound or MRI in the general 
population of women with dense breasts although modeling studies suggest that supplemental 
ultrasound following a negative mammogram may increase cancer detection but at the cost of 
substantially increased false-positive rates (15). Over 90 genetic susceptibility loci have been 
identified (7), but common genetic variants or polygenic risk scores are yet to be incorporated 
into screening recommendations; statistical modeling suggests, though, that they could decrease 
the number needed to screen while preserving the ability to identify most currently screen-
detectable cancers (9). Given the modest contribution of genetic factors to breast cancer risk, 
environmental factors ought to be included in risk models used for stratification.  
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Cervical Cancer Screening 
 Virtually all cases of cervical cancer and precancer are caused by persistent infection 
with certain common sexually transmitted human papillomaviruses (HPV) (16). HPV infection is 
typically acquired in late adolescence and early adulthood, and most infections are controlled by 
the immune system or clear without intervention within a year or two. Women with persistent 
infection have increased risk of cervical precancer that can progress to invasive cancer. In the 
US, acceptable cervical cancer screening includes Pap testing, HPV DNA/RNA testing, or both 
(co-testing); the goal is to detect and treat precancer to prevent cervical cancer morbidity and 
mortality. It appears that the advent of HPV vaccination and accurate HPV tests will make the 
use of screening Pap alone obsolete (17).  
An emerging strategy is to screen, using HPV testing only, women in the general 
population who are at greatest risk, based on age and prior screening experience. The negative 
predictive value of an HPV test is extremely high, and prospective observational studies 
combined with our understanding of the natural history of cervical cancer suggest that screening 
using HPV alone every three years or co-testing every five years provides a reasonable balance 
of efficacy and overtreatment, although there is widespread resistance in the US to a five-year 
interval (18, 19). Frequent HPV testing detects many new HPV infections destined to clear and 
co-testing leads to detection of cervical abnormalities that are especially prone to regression. 
Researchers are looking to discover and validate biomarkers that indicate high risk of precancer 
among HPV-positive women.  
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Colorectal Cancer Screening 
Colorectal cancer screening recommendations in the US general population reflect a 
“menu” approach (20-22). The USPSTF 2016 guidelines (20) strongly recommend screening for 
individuals aged 50 to 75 years and provide seven acceptable strategies that reflect six unique 
modalities; no strategy is recommended over another. The guidelines state that the decision to be 
screened from ages 76 to 85 should take into account overall health and previous screening 
history. Data from the 2013 National Health Interview Survey indicate that only 58% of the US 
population was adherent with the 2008 USPSTF recommendations for colorectal cancer 
screening between 2010 and 2013, with rates of adherence lower among those who are less 
educated or have lower incomes (23). 
The following scenario illustrates the type of challenges faced by clinicians when 
advising patients on colorectal cancer screening. A 55 year-old man has a history of two negative 
colonoscopies at ages 40 and 50. However, his father was diagnosed with colorectal cancer at 
age 40. The presence of family history at a young age suggests the need for continued screening, 
but the clinician contemplates recommending for future exams a less invasive modality or a 15-
year interval between colonoscopies. Unfortunately, the information needed to assess the 
potential value of different scenarios for this patient is lacking. These data are critical for the 
successful implementation of precision screening, and as such, their collection must become a 
research priority.  
 
Lung Cancer Screening 
 Lung cancer screening with low-dose computed tomography (LDCT) is recommended 
based on the results of the National Lung Screening Trial (NLST), which enrolled individuals at 
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high risk due to older age and extensive smoking history. LDCT screening reduced lung cancer 
mortality by 20%, corresponding to an absolute reduction of 3 lung cancer deaths per 1,000 
screened (24). The baseline risk of death from lung cancer varied widely however, ranging from 
less than 0.55% in the lowest risk quintile to >2% in the highest quintile of the control arm, and 
88% of the lung cancer deaths prevented by CT screening were observed in the three highest risk 
quintiles (25). 
Models have been developed to estimate risk of lung cancer diagnosis and death (25-28). 
They facilitate precision screening by providing individualized risk estimates to be used during 
shared decision making visits. Other models are available to estimate risk of complications from 
diagnostic evaluation of a positive screen (29). A comprehensive shared decision making 
approach that provides risk information at all decision points in the screening process, from the 
choice to be screened to lung cancer treatment, would be clinically useful as well.  
Precision screening for lung cancer could potentially benefit from the development of 
biomarkers that can be used to identify an especially high-risk target population, discriminate 
between patients with true positive and false positive test results, and discriminate between 
indolent and aggressive tumors. However, the molecular heterogeneity of lung cancer suggests 
that panels of markers will be necessary, and that tradeoffs between imperfect sensitivity and 
specificity will be unavoidable.    
 
Prostate Cancer Screening 
 There have been two large-scale randomized controlled trials (RCTs) of prostate cancer 
screening in the general population using serum prostate specific antigen (PSA). The European 
Randomized Study of Screening for Prostate Cancer (ERSPC) reported a 21% relative reduction 
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in prostate cancer mortality at 13 years of follow-up, although the reduction was accompanied by 
a 57% increase in incident disease (30). In ERSPC, 781 men needed to be screened to 
prevent one prostate cancer death, and 27 additional prostate cancers had to be diagnosed. The 
Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial found no reduction in 
prostate cancer mortality (31). Despite methodological issues with both studies, the findings 
were used by the USPSTF to recommend against PSA screening and by the ACS to recommend 
informed decision making (32). Genome-wide association studies have identified 100 common 
prostate cancer variants, and while each confers a small risk, in combination they might produce 
useful risk stratification (33, 34). A screening program that targets men at or above the 50th 
percentile of genetic risk is predicted to detect over 75% of cancers (10). While many questions 
must be answered before such a targeted screening program could be introduced, the approach 
has the potential to maximize the benefit of screening while minimizing the harms. 
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CROSS-CUTTING ISSUES IN PRECISION CANCER SCREENING 
In the afternoon, participants attended one of five breakout sessions. Each session was 
facilitated by a single researcher with expertise in the discussion topic. Topics were chosen to 
reflect broader issues surrounding precision cancer screening and its possible implementation.  
 
Risk Prediction and Microsimulation Modeling 
 Risk prediction models can be used to identify individuals in the general population at 
differing risk for cancer death, and could be used to choose more or less aggressive screening 
regimens. Microsimulation modeling can compare outcomes arising from potential and varied 
screening strategies (35, 36). Epidemiologic methods and data can be used to improve 
conceptualization, construction, and implementation of these models. For example, van Hees et 
al developed a risk prediction model for colonoscopy screening in the elderly based on past 
screening history, family history of cancer, colorectal cancer risk factors, and comorbidity (37). 
Data derived from population science can provide information on disease complexity for models; 
for example, prospectively collected data on breast density would provide information to model 
how density changes over time. Unfortunately, commonly-used metrics of predictive 
performance, such as sensitivity, specificity, and AUC, are limited in their usefulness, and no 
unifying method of model assessment currently exists. Furthermore, model inputs are central to 
the value of any model; therefore, they must be chosen carefully and their limitations understood.  
 
Health Services and Clinical Implementation 
 Because evidence concerning precision screening in the general population is just 
beginning to accumulate, it may be premature to discuss implementation. Nevertheless, 
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consideration of likely challenges is critical as we begin to discuss possible screening strategies. 
Expert groups convened by the Collaborative Oncological Gene-Environment Study (COGS) 
identified key ethical, social and logistical aspects needed to support incorporation of genetic 
information into population-based screening in European settings (38). Logistical aspects 
included the need to establish competencies in the healthcare community and assess acceptability 
and cost-effectiveness of stratified screening programs prior to implementation (39). In the US, 
implementation strategies will need to address those needs as well as challenges raised by the 
non-integrated structure of the healthcare system. 
As exemplified by current challenges in healthcare delivery, screening strategies that are 
difficult to integrate into clinical workflows are unlikely to be successful, even if they can 
decrease cancer mortality in controlled environments. Implementation may further be hampered 
by the opportunistic way in which cancer screening is usually delivered in the US due to lack of 
centralized information on medical history, especially previous screening experience. It also will 
be necessary to respect values and preferences of patients with evidence-driven care. 
Implementation also will likely vary due to differences in provider and health care system 
practices, which will in turn impact patient experiences and outcomes, as well as quality 
improvement and metrics, provider and system incentives, and population health. 
 
Leveraging Existing Data Sources and Infrastructure 
 Established epidemiological cohorts and screening registries can and will continue to 
provide invaluable and unique information for the development and evaluation of risk prediction 
models. Evaluating the risk of rare tumor subtypes and risk among population subgroups requires 
longitudinal data from very large cohorts. For evaluating precision screening, cohorts and 
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registries need to have information, at a minimum, on baseline genetic and non-genetic risk 
factors, detection method, prognostic tumor characteristics, and biospecimens for future 
genotyping. Data collection on provider and facility characteristics adds important information 
for multi-level modeling and confounder adjustment. It is imperative that data come from 
patients who are seen in settings representative of community practice so that findings are 
generalizable. Given the needed large sample size and long follow-up time, it will not be 
possible to compare all potential screening strategies using RCTs; therefore, observational data 
from large cohorts and registries, analyzed with causal inference methods, need to be used. 
Existing infrastructure also can provide a springboard for the efficient conduct of pragmatic 
comparative effectiveness trials. 
 
Behavioral Aspects and Health Disparities 
 Health care disparities caused by geographic, socioeconomic, demographic and 
healthcare access factors may be exacerbated if not considered prior to implementation of 
precision cancer screening practices, should that ultimately occur. Behavioral and social sciences 
research is needed to address knowledge gaps in areas relevant to implementation. For example, 
data on patient risk factors often relies on patient self-report (40, 41), but accuracy of self-report 
varies across patient subgroups, with lower sensitivity and specificity observed for minority 
patients (42). Thus, methods to improve accurate reporting are needed. In addition, patient-
centered communication and shared decision-making will be essential to help patients handle 
uncertainty (43, 44). Enabling effective communication will be particularly challenging for 
providers caring for patients with low health literacy or cultural barriers to acceptance. Precision 
cancer screening delivery cannot solely rest on already-overloaded physicians, and case 
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managers, nurse navigators, and genetics counselors could help to deliver information about 
screening choices. If a multidisciplinary team approach is employed (45, 46), responsibilities of 
each member must be defined and necessary resources identified. To facilitate healthcare 
delivery, electronic health records should provide clinical decision support; store information 
needed to identify high-risk patients, document provider recommendations and patient decisions, 
and track management of abnormal results. The existence of these capabilities, particularly in 
low-resource healthcare settings, may lessen or prevent disparities that often accompany 
screening implementation (47, 48) . 
           
Evaluating Differential Effectiveness of Screening by Demographics, Genetics, and Other 
Factors 
 A prevailing strategy in precision screening in the general population is to identify 
subgroups that have varied cancer risk due to factors such as demographics, family history, and 
genetics. Receiving less attention is the possibility of differential effectiveness of screening for 
those groups. Differential effectiveness refers to the situation in which the mortality reduction 
attributable to screening, measured as a percent reduction, varies according to some identifiable 
factor. For example, the NLST showed no statistically significant differential effects on the lung 
cancer mortality percent reduction for age dichotomized at 65 years old, current versus former 
smoking status, or sex, although the observed mortality reduction for women (27%) was about 
three times that for men (8%) (49). This example highlights the difficulty in evaluating 
heterogeneous effectiveness, as screening trials rarely have sufficient power to detect interactions 
of typical magnitude. In addition, the small number of screening trials for a specific modality 
means it usually is not possible to test the reproducibility of findings, and often there are no 
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plausible explanations for potential differential effectiveness. Therefore, it is usually assumed 
that the mortality reduction is constant across major demographic or risk factor categories. This 
assumption seems reasonable unless there is a strong reason to believe otherwise or strong 
evidence to the contrary. 
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DISCUSSION 
 NCI’s Precision Cancer Screening symposium provided a venue in which to educate 
attendees about the state of the evidence; it also provided a space in which important discussions 
surrounding next steps in precision screening research could occur. The symposium was not 
intended to produce recommendations, but the organizers did expect that themes would emerge 
as attendees, who represented multiple disciplines and had varied points of view, wrestled with 
the difficult issues that surround the possibility of moving such a complex and multi-faceted 
research agenda forward. The most prominent themes to emerge were strength of evidence and 
feasibility of implementation.  
With regard to strength of evidence, some attendees felt that efficacy of precision cancer 
screening strategies for the general population could not be assessed without RCTs. Others felt 
that well-done observational studies and statistical modeling could provide useful information to 
make policy decisions if decisions were made carefully. Arguments for and against types of 
evidence were as expected. Those who felt that strategies must be tested in RCTs argued that 
screening always causes harm but benefit is never guaranteed (50). Those who felt that 
observational and statistical modeling data could suffice argued that it would be impossible to 
test all possible strategies with RCTs and that dissemination of precision screening strategies 
would likely happen before RCTs were completed, should trials occur. Each point of view can be 
defended, yet the solution to moving precision cancer screening forward likely rests on a 
compromise: some questions, perhaps those for which little data are available or represent new 
technology, will require RCTs, while others, perhaps those for which RCTs have been done to 
address over-arching or related questions, can utilize existing RCT data, cohort data, or cancer 
registries to inform modeling of screening harms and benefits.  
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With regard to feasibility of implementation, attendees pointed out challenges and 
possible approaches for the US. Attendees questioned whether the US health care system, 
already stretched thin, could handle incorporation of additional data needed to determine whether 
patients are at risk based on more complex information than age, for example. Others questioned 
how precision cancer screening would be implemented in US areas with fewer resources, such as 
those that are served primarily by safety net systems. Attendees pointed out that implementation 
issues are typically overlooked until efficacy has been assessed, but that concurrent assessment 
of patient acceptability and other implementation issues could allow for rapid uptake if precision 
screening strategies are shown to be of benefit.  
Due to time constraints, health service changes that would need to accompany precision 
cancer screening in the US were not extensively discussed at the symposium, but were 
acknowledged as barriers to implementation. One needed change would involve “un-
recommending” screening for segments of the US population identified through risk-
stratification as being at low risk of cancer. That could in turn lead to elimination of the option to 
be screened for those who are dependent on health insurance to pay for preventive services. 
However, many cancer organizations, both research and advocacy organizations, continue to 
stress the centrality of screening for all to reduce the cancer burden, even as the harms of 
screening are better understood, quantified, and publicized. The contradictory messages that 
could result would leave the public confused and clinicians with yet another difficult, time-
consuming task. Other changes would include reframing of cancer as a disease that in some 
instances is unlikely to be fatal, and one for which earliest detection may not always be 
necessary for cure. Perhaps the biggest challenge in moving forward with exploration of 
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precision cancer screening is to undo ingrained and historically-rooted, but not universally true, 
beliefs about cancer.  
A fundamental tension exists in cancer screening: we need to screen as efficiently as 
possible but want to prevent as many cancer deaths as possible. Realistic manners in which to 
ameliorate that tension seem elusive. Precision cancer screening in the general population may 
prove helpful, but to rush to choose it at this point in time would be unwise. Additional 
discussion needs to occur to identify the high priority research areas in precision cancer 
screening and to map out plans to gather the necessary evidence to determine whether 
implementation is likely to be feasible and beneficial.  
  
22 
 
REFERENCES 
1. The Precision Medicine Initiative. [cited May 5, 2016]. Available from: 
https://www.whitehouse.gov/precision-medicine. 
2. A Conversation with NCI Acting Director, Dr. Douglas R. Lowy: Precision Medicine and the 
NCI Budget. [cited May 5, 2016]. Available from: http://www.cancer.gov/about-
nci/organization/oar/news-updates/lowy-precision-medicine-webinar-transcript.pdf. 
3. Collins  FS, Varmus  H. A New Initiative on Precision Medicine. N Engl J Med 
2015;372:793-5. 
4. Khoury MJ, Gwinn ML, Glasgow RE, Kramer BS. A population approach to precision 
medicine. Am J Prev Med 2012;42:639-45. 
5. Precision Cancer Screening in the General Population: Evidence, Epidemiology, and Next 
Steps. [cited May 5, 2016]. Available from: http://epi.grants.cancer.gov/events/precision/. 
6. Dent T, Jbilou J, Rafi I, Segnan N, Tornberg S, Chowdhury S, et al. Stratified cancer 
screening: the practicalities of implementation. Public Health Genomics 2013;16:94-9. 
7. Michailidou K, Beesley J, Lindstrom S, Canisius S, Dennis J, Lush MJ, et al. Genome-wide 
association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for 
breast cancer. Nat Genet 2015;47:373-80. 
8. Garcia-Closas M, Gunsoy NB, Chatterjee N. Combined associations of genetic and 
environmental risk factors: implications for prevention of breast cancer. J Natl Cancer Inst 
2014;106:dju305. 
9. Pashayan N, Duffy SW, Chowdhury S, Dent T, Burton H, Neal DE, et al. Polygenic 
susceptibility to prostate and breast cancer: implications for personalised screening. Br J 
Cancer 2011;104:1656-63. 
23 
 
10. Pashayan N, Duffy SW, Neal DE, Hamdy FC, Donovan JL, Martin RM, et al. Implications of 
polygenic risk-stratified screening for prostate cancer on overdiagnosis. Genet Med 
2015;17:789-95. 
11. Pashayan N, Pharoah PD, Schleutker J, Talala K, Tammela T, Maattanen L, et al. Reducing 
overdiagnosis by polygenic risk-stratified screening: findings from the Finnish section of the 
ERSPC. Br J Cancer 2015;113:1086-93. 
12. Oeffinger KC, Fontham ET, Etzioni R, Herzig A, Michaelson JS, Shih YC, et al. Breast 
Cancer Screening for Women at Average Risk: 2015 Guideline Update From the American 
Cancer Society. JAMA 2015;314:1599-614. 
13. van Ravesteyn NT, Miglioretti DL, Stout NK, Lee SJ, Schechter CB, Buist DS, et al. Tipping 
the balance of benefits and harms to favor screening mammography starting at age 40 years: 
a comparative modeling study of risk. Ann Intern Med 2012;156:609-17. 
14. Kerlikowske K, Zhu W, Hubbard RA, Geller B, Dittus K, Braithwaite D, et al. Outcomes of 
screening mammography by frequency, breast density, and postmenopausal hormone 
therapy. JAMA Intern Med 2013;173:807-16. 
15. Sprague BL, Stout NK, Schechter C, van Ravesteyn NT, Cevik M, Alagoz O, et al. Benefits, 
harms, and cost-effectiveness of supplemental ultrasonography screening for women with 
dense breasts. Ann Intern Med 2015;162:157-66. 
16. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus 
and cervical cancer. Lancet 2007;370:890-907. 
17. Schiffman M, Wentzensen N. A Suggested Approach to Simplify and Improve Cervical 
Screening in the United States. J Low Genit Tract Dis 2016;20:1-7. 
24 
 
18. Huh WK, Ault KA, Chelmow D, Davey DD, Goulart RA, Garcia FA, et al. Use of primary 
high-risk human papillomavirus testing for cervical cancer screening: interim clinical 
guidance. Gynecol Oncol 2015;136:178-82. 
19. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, et al. American 
Cancer Society, American Society for Colposcopy and Cervical Pathology, and American 
Society for Clinical Pathology screening guidelines for the prevention and early detection of 
cervical cancer. CA Cancer J Clin 2012;62:147-72. 
20. United States Preventive Services Task Force. Screening for Colorectal Cancer: US 
Preventive Services Task Force Recommendation Statement. JAMA 2016;315:2564-75. 
21. Ransohoff DF, Sox HC. Clinical Practice Guidelines for Colorectal Cancer Screening: New 
Recommendations and New Challenges. JAMA 2016;315:2529-31. 
22. Levin B, Lieberman DA, McFarland B, Smith RA, Brooks D, Andrews KS, et al. Screening 
and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a 
joint guideline from the American Cancer Society, the US Multi-Society Task Force on 
Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin 2008;58:130-
60. 
23. Sabatino SA, White MC, Thompson TD, Klabunde CN, Centers for Disease C, Prevention. 
Cancer screening test use - United States, 2013. MMWR Morb Mortal Wkly Rep 
2015;64:464-8. 
24. National Lung Screening Trial Research T, Aberle DR, Adams AM, Berg CD, Black WC, 
Clapp JD, et al. Reduced lung-cancer mortality with low-dose computed tomographic 
screening. N Engl J Med 2011;365:395-409. 
25 
 
25. Kovalchik SA, Tammemagi M, Berg CD, Caporaso NE, Riley TL, Korch M, et al. Targeting 
of low-dose CT screening according to the risk of lung-cancer death. N Engl J Med 
2013;369:245-54. 
26. Bach PB, Kattan MW, Thornquist MD, Kris MG, Tate RC, Barnett MJ, et al. Variations in 
lung cancer risk among smokers. J Natl Cancer Inst 2003;95:470-8. 
27. Spitz MR, Hong WK, Amos CI, Wu X, Schabath MB, Dong Q, et al. A risk model for 
prediction of lung cancer. J Natl Cancer Inst 2007;99:715-26. 
28. Tammemagi MC, Katki HA, Hocking WG, Church TR, Caporaso N, Kvale PA, et al. 
Selection criteria for lung-cancer screening. N Engl J Med 2013;368:728-36. 
29. Wiener RS, Schwartz LM, Woloshin S, Welch HG. Population-based risk for complications 
after transthoracic needle lung biopsy of a pulmonary nodule: an analysis of discharge 
records. Ann Intern Med 2011;155:137-44. 
30. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V, et al. Screening and 
prostate cancer mortality: results of the European Randomised Study of Screening for 
Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 2014;384:2027-35. 
31. Andriole GL, Crawford ED, Grubb RL, 3rd, Buys SS, Chia D, Church TR, et al. Prostate 
cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer 
Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst 
2012;104:125-32. 
32. Smith RA, Manassaram-Baptiste D, Brooks D, Doroshenk M, Fedewa S, Saslow D, et al. 
Cancer screening in the United States, 2015: a review of current American cancer society 
guidelines and current issues in cancer screening. CA Cancer J Clin 2015;65:30-54. 
26 
 
33. Al Olama AA, Kote-Jarai Z, Berndt SI, Conti DV, Schumacher F, Han Y, et al. A meta-
analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. Nat 
Genet 2014;46:1103-9. 
34. Eeles RA, Olama AA, Benlloch S, Saunders EJ, Leongamornlert DA, Tymrakiewicz M, et al. 
Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom 
genotyping array. Nat Genet 2013;45:385-91. 
35. Zauber AG, Lansdorp-Vogelaar I, Knudsen AB, Wilschut J, van Ballegooijen M, Kuntz KM. 
Evaluating test strategies for colorectal cancer screening: a decision analysis for the U.S. 
Preventive Services Task Force. Ann Intern Med 2008;149:659-69. 
36. Knudsen AB, Zauber AG, Rutter CM, Naber SK, Doria-Rose VP, Pabiniak C, et al. 
Estimation of Benefits, Burden, and Harms of Colorectal Cancer Screening Strategies: 
Modeling Study for the US Preventive Services Task Force. JAMA 2016;315:2595-609. 
37. van Hees F, Saini SD, Lansdorp-Vogelaar I, Vijan S, Meester RG, de Koning HJ, et al. 
Personalizing colonoscopy screening for elderly individuals based on screening history, 
cancer risk, and comorbidity status could increase cost effectiveness. Gastroenterology 
2015;149:1425-37. 
38. Stratified screening for cancer: recommendations and analysis from the COGS project. [cited 
May 5, 2016]. Available from: http://www.phgfoundation.org/file/15380/. 
39. Chowdhury S, Dent T, Pashayan N, Hall A, Lyratzopoulos G, Hallowell N, et al. 
Incorporating genomics into breast and prostate cancer screening: assessing the implications. 
Genet Med 2013;15:423-32. 
27 
 
40. Newell SA, Girgis A, Sanson-Fisher RW, Savolainen NJ. The accuracy of self-reported 
health behaviors and risk factors relating to cancer and cardiovascular disease in the general 
population: a critical review. Am J Prev Med 1999;17:211-29. 
41. Vernon SW, Meissner H, Klabunde C, Rimer BK, Ahnen DJ, Bastani R, et al. Measures for 
ascertaining use of colorectal cancer screening in behavioral, health services, and 
epidemiologic research. Cancer Epidemiol Biomarkers Prev 2004;13:898-905. 
42. Rauscher GH, Johnson TP, Cho YI, Walk JA. Accuracy of self-reported cancer-screening 
histories: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2008;17:748-57. 
43. Patient-centered communication in cancer care. [cited 5/10/2016]. Available from: 
http://appliedresearch.cancer.gov/areas/pcc/communication/pcc_monograph.pdf. 
44. Han PK, Klein WM, Lehman TC, Massett H, Lee SC, Freedman AN. Laypersons' responses 
to the communication of uncertainty regarding cancer risk estimates. Med Decis Making 
2009;29:391-403. 
45. Chin MH, Clarke AR, Nocon RS, Casey AA, Goddu AP, Keesecker NM, et al. A roadmap 
and best practices for organizations to reduce racial and ethnic disparities in health care. J 
Gen Intern Med 2012;27:992-1000. 
46. Fennell ML, Das IP, Clauser S, Petrelli N, Salner A. The organization of multidisciplinary 
care teams: modeling internal and external influences on cancer care quality. J Natl Cancer 
Inst Monogr 2010;2010:72-80. 
47. DesRoches CM, Charles D, Furukawa MF, Joshi MS, Kralovec P, Mostashari F, et al. 
Adoption of electronic health records grows rapidly, but fewer than half of US hospitals had 
at least a basic system in 2012. Health Aff (Millwood) 2013;32:1478-85. 
28 
 
48. Yamin CK, Emani S, Williams DH, Lipsitz SR, Karson AS, Wald JS, et al. The digital divide 
in adoption and use of a personal health record. Arch Intern Med 2011;171:568-74. 
49. Pinsky PF, Church TR, Izmirlian G, Kramer BS. The National Lung Screening Trial: results 
stratified by demographics, smoking history, and lung cancer histology. Cancer 
2013;119:3976-83. 
50. Croswell JM, Ransohoff DF, Kramer BS. Principles of cancer screening: lessons from 
history and study design issues. Semin Oncol 2010;37:202-15. 
 
